

# Gaelle Quereux

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3228166/publications.pdf>

Version: 2024-02-01

36  
papers

1,141  
citations

516710

16  
h-index

395702

33  
g-index

39  
all docs

39  
docs citations

39  
times ranked

1571  
citing authors

#	ARTICLE	IF	CITATIONS
1	First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. <i>Lancet, The</i> , 2017, 389, 2031-2040.	13.7	438
2	Use of Smartphones for Early Detection of Melanoma: Systematic Review. <i>Journal of Medical Internet Research</i> , 2018, 20, e135.	4.3	84
3	Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General Population. <i>Journal of Investigative Dermatology</i> , 2019, 139, 835-841.	0.7	69
4	Large International Validation of ABSIS and PDAI Pemphigus Severity Scores. <i>Journal of Investigative Dermatology</i> , 2019, 139, 31-37.	0.7	55
5	Photodynamic therapy with methyl-aminolevulinic acid for paucilesional mycosis fungoides: A prospective open study and review of the literature. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 890-897.	1.2	43
6	Severe radiotherapy-induced extracutaneous toxicity under vemurafenib. <i>European Journal of Dermatology</i> , 2013, 23, 879-881.	0.6	40
7	Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy. <i>JAMA Dermatology</i> , 2020, 156, 545.	4.1	40
8	Development of an individual score for melanoma risk. <i>European Journal of Cancer Prevention</i> , 2011, 20, 217-224.	1.3	30
9	Validation of the Self-Assessment of Melanoma Risk Score for a melanoma-targeted screening. <i>European Journal of Cancer Prevention</i> , 2012, 21, 588-595.	1.3	30
10	Incidence and Mortality of Pemphigus in France. <i>Journal of Investigative Dermatology</i> , 2019, 139, 469-473.	0.7	30
11	Fotemustine for the treatment of melanoma. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2891-2904.	1.8	24
12	Bexarotene in cutaneous T-cell lymphoma: third retrospective study of long-term cohort and review of the literature. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1711-1721.	1.8	22
13	Efficacy and tolerance of photodynamic therapy for vulvar Paget's disease: a multicentric retrospective study. <i>European Journal of Dermatology</i> , 2018, 28, 351-355.	0.6	21
14	Prospective trial on a school-based skin cancer prevention project. <i>European Journal of Cancer Prevention</i> , 2009, 18, 133-144.	1.3	18
15	Sudden Onset of an Aggressive Cutaneous Lymphoma in a Young Patient With Psoriasis: Role of Immunosuppressants. <i>Acta Dermato-Venereologica</i> , 2010, 90, 616-620.	1.3	18
16	Incidence and severity of COVID-19 in patients with autoimmune blistering skin diseases: A nationwide study. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 494-497.	1.2	18
17	Chemotherapy efficacy after first-line immunotherapy in 18 advanced melanoma patients. <i>Medicine (United States)</i> , 2020, 99, e21329.	1.0	17
18	Creation and test of a questionnaire for self-assessment of melanoma risk factors. <i>European Journal of Cancer Prevention</i> , 2010, 19, 48-54.	1.3	16

#	ARTICLE	IF	CITATIONS
19	Routine bone marrow biopsy in the initial evaluation of primary cutaneous B-cell lymphoma does not appear justified. <i>European Journal of Dermatology</i> , 2009, 19, 216-220.	0.6	15
20	Efficacy and safety of nivolumab in metastatic melanoma: real-world practice. <i>European Journal of Dermatology</i> , 2019, 29, 315-321.	0.6	14
21	Drug reaction with eosinophilia and systemic symptoms syndrome induced by combination of vemurafenib and cobimetinib in melanoma: A series of 11 cases. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 558-562.	1.2	13
22	Systemic Rituximab in Multifocal Primary Cutaneous Follicle Centre Lymphoma. <i>Acta Dermato-Venereologica</i> , 2011, 91, 562-567.	1.3	12
23	Proposal for an annual skin examination by a general practitioner for patients at high risk for melanoma: a French cohort study. <i>BMJ Open</i> , 2015, 5, e007471.	1.9	12
24	A comparison of posttraumatic growth changes in breast cancer and melanoma. <i>Health Psychology</i> , 2019, 38, 878-887.	1.6	12
25	Patients at elevated risk of melanoma: Individual predictors of non-compliance to GP referral for a dermatologist consultation. <i>Preventive Medicine</i> , 2014, 64, 48-53.	3.4	11
26	Sexual well-being in patients with vulvar disease: results from a preliminary prospective matched case-control study. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2015, 194, 106-110.	1.1	8
27	Efficient treatment of a metastatic melanoma patient with a combination of BRAF and MEK inhibitors based on circulating tumor DNA analysis: a case report. <i>BMC Research Notes</i> , 2017, 10, 320.	1.4	7
28	Impact of Mogamulizumab in Real-Life Advanced Cutaneous T-Cell Lymphomas: A Multicentric Retrospective Cohort Study. <i>Cancers</i> , 2022, 14, 1659.	3.7	7
29	5-fluorouracil chemowraps for the treatment of multiple actinic keratoses. <i>European Journal of Dermatology</i> , 2017, 27, 635-640.	0.6	6
30	Dramatic response of an inoperable Merkel cell carcinoma with imatinib. <i>JAAD Case Reports</i> , 2016, 2, 16-18.	0.8	4
31	Evaluation of the role of human herpes virus 6 and 8 in parapsoriasis. <i>Experimental Dermatology</i> , 2009, 18, 357-361.	2.9	3
32	Spectacular response of metastatic vulval Crohn's disease to infliximab treatment. <i>International Journal of Dermatology</i> , 2016, 55, 1146-1148.	1.0	3
33	Exceptional Association of Syringotropic Mycosis Fungoides with Chronic Lymphocytic Leukaemia. <i>Acta Dermato-Venereologica</i> , 2016, 96, 263-264.	1.3	1
34	BRAF mutation in circulating DNA of melanoma patients at baseline and intertumor heterogeneity. <i>Journal of Clinical Oncology</i> , 2014, 32, 9017-9017.	1.6	0
35	Detection of BRAF mutations in the plasma of melanoma patients as an early marker of treatment efficiency. <i>Journal of Clinical Oncology</i> , 2014, 32, 9069-9069.	1.6	0
36	Incidence and characteristics of melanoma brain metastases appearing during vemurafenib treatment. <i>Journal of Clinical Oncology</i> , 2014, 32, 9042-9042.	1.6	0